U.S. markets close in 22 minutes

CMIC HOLDINGS Co., Ltd. (2309.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
1,634.00+12.00 (+0.74%)
At close: 03:15PM JST


Hamamatsucho Building
1-1-1 Shibaura Minato-ku
Tokyo 105-0023
81 3 6779 8000

IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Kazuo Nakamura Ph.D.Founder, Chairman, CEO & Division Director of Healthcare Revolution Bus.N/AN/A1946
Mr. Yoichi KuwajimaVice Chairman & Sr. AdvisorN/AN/A1957
Mr. Yoshiyuke InamotoHead of Alliances & Vice ChairmanN/AN/AN/A
Ms. Keiko OishiPres, COO, Division Director of CRO Bus. & Representative DirectorN/AN/A1957
Mr. Wataru MochizukiCFO & Corp. DirectorN/AN/A1961
Mr. Teruo SaitoC.L.C.O.N/AN/AN/A
Mr. Makoto MatsukawaVP, Head of Corp. Devel., Division Director of CDMO Bus. & Corp. DirectorN/AN/A1960
Mr. Takashi SanoSr. Advisor & Academy HeadN/AN/A1947
Mr. Mike SugaSr. VPN/AN/AN/A
Mr. Toru FujiedaCorp. Director of Consulting & Navigation Unit and Corp. DirectorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.


CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. It operates in two segments: Pharmaceutical Solutions and Healthcare Solutions. The company offers clinical trial services, including clinical operations and trials, data management, clinical caretaker, patient recruitment, pharmacovigilance, project management, audit and quality assurance, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance pricing, and product life cycle management consulting services. It also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, technology transfer, as well as formulation, process, and analytical development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, the company offers patient and healthcare services, such as drug adherence support program, harmo, Helc+, prescription drug database, and selcheck services; and post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing, clinical research coordinating, clinical site administration, and site management services. It has a partnership with Science 37, Inc. to decentralize clinical trials and enhance the development of treatments. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.

Corporate Governance

CMIC HOLDINGS Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.